The ETV6‐NTRK3 fusion gene encodes a tyrosine kinase that promotes oncogenesis by causing increased cell proliferation and perpetuates tumor cells [29-32]. Certain molecular disorders in malignant SGCs have been identified recently, therefore, to confirm the diagnosis in morphologically ambiguous tumors, molecular testing delivers crucial information that benefits patients [6,33,34]. This evidence concerns the gene ETV6 and neoplasm.